Predicting pathological complete response in breast cancer early

Affiliations

Comment

David Groheux. Lancet Oncol. 2014 Dec.

. 2014 Dec;15(13):1415-1416.

doi: 10.1016/S1470-2045(14)71020-4. Epub 2014 Oct 30.

¹ Nuclear Medicine Department, Saint-Louis Hospital, 1 Avenue Claude Vellefaux, 75475 Paris Cedex 10, France. Electronic address: dgroheux@yahoo.fr.

No abstract available

Comment on

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupré PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo-Riedinger A. Coudert B, et al. Lancet Oncol. 2014 Dec;15(13):1493-1502. doi: 10.1016/S1470-2045(14)70475-9. Epub 2014 Oct 30. Lancet Oncol. 2014. PMID: 25456368 Clinical Trial.